PL BioScience Secures Japan PMDA Certification for Cell Culture Media, Advancing Regenerative Medicine Development
核心洞察
PL BioScience GmbH (搜索) received Japan's first Material Qualification Certificate from PMDA for its ELAREM™ Ultimate-FD PLUS (搜索) cell culture media, marking a regulatory milestone for the German company.
The gamma-irradiated Human Platelet Lysate (搜索) product features viral inactivation technology covered by PL BioScience's exclusive global patent, positioning it uniquely in the market.
The GMP-grade certification enables Japanese regenerative medicine (搜索) developers to reduce CMC risks and streamline supplier qualification processes for clinical applications.
PL BioScience GmbH (搜索) has achieved a significant regulatory milestone with Japan's Pharmaceuticals and Medical Devices Agency (搜索) (PMDA) issuing a Material Qualification Certificate for ELAREM™ Ultimate-FD PLUS (搜索) (GMP Grade) cell culture media. This certification represents the first regulatory approval of ELAREM™ for clinical applications in Japan, marking a critical advancement for the German life science company's expansion into Asian markets.
Unique Technology Platform Gains Regulatory Recognition
ELAREM™ Ultimate-FD PLUS (搜索) is a gamma-irradiated Human Platelet Lysate (搜索) (HPL (搜索)) designed to ensure viral inactivation, a process for which PL BioScience holds the only global patent. The product is a fibrinogen-depleted and anticoagulant-free HPL of EU origin that serves as a xeno-free cell culture supplement supporting efficient and safe in vitro expansion of primary cells and cell lines.
"The PMDA material qualification is an important step for PL BioScience as it allows us to support developers in Japan who are advancing regenerative medicine (搜索) and other clinical programs that require certainty in raw material quality and safety compliance," said Dr. Hatim Hemeda, CEO of PL BioScience.
Strategic Impact on Japanese Market Development
The certification provides the product credibility necessary to accelerate adoption among Japanese sponsors and Contract Development and Manufacturing Organizations (CDMOs). This regulatory approval addresses critical needs in cell and regenerative medicine (搜索) programs where media choice can materially affect consistency and scalability.
Jungsoo Park, VP of Marketing and Sales at PL BioScience, emphasized the practical benefits: "By having a GMP-grade, platelet-derived cell culture media formally qualified for clinical use in Japan, developers can de-risk their CMC packages, streamline supplier qualification work, and potentially shorten the path from process development to first-in-human production."
Manufacturing and Quality Standards
The ELAREM™ Ultimate-FD PLUS (搜索) product is manufactured, tested and released in compliance with relevant GMP guidelines. The manufacturing process is patented and specifically suited to cell manufacturing applications requiring proven viral reduction for potential use in clinical trials. This certification enables regenerative medicine (搜索) developers in Japan to move faster with confidence as they design and manufacture investigational products.
Company Background and Market Position
PL BioScience GmbH (搜索), located in Aachen, Germany, specializes in the production and development of Human Platelet Lysate (搜索). The company has pioneered proprietary technology to produce fully artificial HPL (搜索), allowing for a fully lab-made, scalable supply. PL BioScience currently offers a comprehensive portfolio of donor-derived, natural HPL products tailored for applications ranging from academic and preclinical research to cell therapy and biopharmaceutical manufacturing through its ELAREM™ platform.
The PMDA certification positions PL BioScience as the only company worldwide holding a patent for gamma-irradiation of HPL (搜索), covering the manufacturing process for ELAREM™ Ultimate-FD PLUS (搜索). This regulatory milestone serves as a springboard for broader Asia expansion while supporting the seamless translation of regenerative medicine (搜索) breakthroughs from laboratory to patients.